- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02385240
Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
October 20, 2021 updated by: Padagis LLC
To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved rosacea drug product in the treatment of facial erythema of rosacea.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
552
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide IRB approved written informed consent/assent.
- Male or non-pregnant female, ≥ 18 years of age.
- Diagnosis of rosacea with moderate to severe erythema on the face defined as: a score of ≥ 3 on the Clinician's Erythema Assessment (CEA) and a score of ≥ 3 on the Patient's Self-Assessment (PSA) on Visit 1/Day 1 (Baseline) prior to the first application of study medication at hour 0.
- Willing and able to understand and comply with the requirements of the study.
- Be in general good health and free from any clinically significant disease, other than rosacea, that might interfere with the study evaluations.
- Females of childbearing potential in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study
Exclusion Criteria:
- Females who are pregnant, breast feeding, or planning a pregnancy within the study participation period.
- Presence of three (3) or more facial inflammatory lesions of rosacea.
- Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome or depression.
- Other facial conditions that in the Investigator's opinion might interfere with a rosacea diagnosis and/or assessment including but not limited to: acne conglobata, acne fulminans, rhinophyma, facial pustulosis of the chin, peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, actinic keratosis, acne, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis .
- Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial or, in the judgment of the Investigator, would put the subject at undue risk or might confound the study assessments (such as planned hospitalization during the study).
- Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
- Excessive facial hair (such as beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of rosacea.
- History of hypersensitivity or allergy to any ingredient in the study medication.
- Previous enrollment in this study.
- Non-responders to prior treatment with topical brimonidine.
- Currently using any product containing brimonidine tartrate or oxymetazoline.
- Start or change of dose of hormonal treatments.
- Start or change of dose of tricyclic or tetracyclic antidepressants, cardio glycosides, beta blockers or calcium channel blockers or other anti-hypertensive agents 3 months (90 days) prior to baseline or throughout the study. Use of such therapy must remain constant during the study.
- Current treatment with or start of any of the following class of drugs: monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics or alpha-agonists, medicines for psychosis, medicines for hyperactivity
- Use within 6 months (180 days) prior to baseline or during the study of oral retinoids or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
- Use within 12 weeks (84 days) prior to baseline or during the study of systemic immunomodulators
- Use of medicated make-up throughout the study and/or significant change in the use of consumer products within 4 weeks (28 days) of study entry and throughout the study.
- Participation in any clinical study involving an investigational product or device in the 4 weeks (28 days) prior to baseline or throughout the study.
- Use of following topicals on the face within 14 days prior to baseline or during the study of antibiotics and/or prescription anti-inflammatory agents including ophthalmic
- Over the counter (OTC) topical anti-acne medications 7 days prior to baseline
- Chronic, daily use of OTC anti-inflammatory medications for more than 7 days (does not include low-dose aspirin for cardiac prophylaxis), 7 days prior to baseline and throughout the study. Subjects may use acetaminophen for pain relief, as needed throughout the study.
- Use of tanning booths, sun lamps, sunbathing, phototherapy or excessive ultraviolet (UV) exposure to the sun 7 days prior to baseline and throughout the study.
- Use of Niacin ≥500 mg per day within 7 days of study start and throughout the study.
- Use of topical astringents or abrasives within 2 days of study start and throughout the study.
- Use of antipruritics (including antihistamines), spa treatments or chlorine exposure (swimming, etc.) within 24 hours of all study visits (Visit 1 through Visit 3).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test product
Brimonidine Topical Gel, 0.33 percent
|
Other Names:
|
Active Comparator: Reference Product
Brimonidine Topical Gel, 0.33 percent (Reference)
|
Other Names:
|
Placebo Comparator: Placebo gel
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects With Composite Success
Time Frame: Day 15 at hour 6
|
2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales
|
Day 15 at hour 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects With Composite Success
Time Frame: Day 15 at hour 3
|
2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales
|
Day 15 at hour 3
|
Proportion of Subjects With Composite Success
Time Frame: Day 15 at hour 9
|
2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales
|
Day 15 at hour 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
March 5, 2015
First Submitted That Met QC Criteria
March 5, 2015
First Posted (Estimate)
March 11, 2015
Study Record Updates
Last Update Posted (Actual)
October 22, 2021
Last Update Submitted That Met QC Criteria
October 20, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRG-NY-14-022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on Placebo gel
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHealthyUnited States, Puerto Rico
-
NutravaliaSlb PharmaCompletedOverweight and ObesityFrance
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Recruiting
-
Population CouncilCompletedHIV InfectionUnited States
-
Topokine Therapeutics, Inc.SuspendedExcess Submental Fat ("Double Chin")
-
Xinnate ABRegion SkaneCompletedBlister | Epidermolysis Bullosa | Wound of Skin | Varicose Ulcer of Lower LimbSweden
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Kalypsys, Inc.CompletedNeuropathic Pain | Herpes Zoster | Postherpetic Neuralgia | ShinglesUnited States
-
Suzhou Kintor Pharmaceutical Inc,CompletedAcne Vulgaris | Androgenetic AlopeciaUnited States